Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 3, 28 April 2023
Open
Access | Article
Atopic Dermatitis: Mechanism and Topical Treatment Strategies
* Author to whom correspondence should be addressed.
Abstract
Atopic dermatitis is a chronic inflammatory skin disease with a complex pathogenesis relating to immunology, genetic inheritance, and environmental conditions. Various treatments are applied to relieve the symptoms of AD. One of the most common types of medication applied is topical treatments. The review examines the mechanisms of action and pathways for topical corticosteroids, non-steroid topical calcineurin inhibitors, and phosphodiesterase 4 inhibitors based on a wide range of research and studies targeting AD. The three treatment strategies are compared under different disease conditions. The review suggests that to maximize the effectiveness and minimize side effects, the application of each type of medication should be carefully considered depending on the severity of AD conditions and the individual's physical condition.
Keywords
phosphodiesterase 4 inhibitor, topical corticosteroids, topical calcineurin Inhibitors, atopic dermatitis
References
1. Pugliarello S, Cozzi A, Gisondi P, Girolomoni G. Phenotypes of atopic dermatitis: Phenotypes of atopic dermatitis. [J] J Dtsch Dermatol Ges. 2011;9(1), pp.12-20.
2. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. [J] Nat Rev Drug Discov. 2022;21(1), pp.21-40.
3. Kader HA, Azeem M, Jwayed SA, Al-Shehhi A, Tabassum A, Ayoub MA, et al. Current insights into immunology and novel therapeutics of atopic dermatitis. [J] Cells. 2021;10(6), pp. 1392.
4. Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: The yin and yang of cutaneous inflammation. [J] Front Immunol. 2015;6, pp. 353.
5. Junttila IS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. [J] Front Immunol. 2018, pp. 9.
6. Salimian J, Salehi Z, Ahmadi A, Emamvirdizadeh A, Davoudi SM, Karimi M, et al. Atopic dermatitis: molecular, cellular, and clinical aspects. [J] Mol Biol Rep. 2022;49(4), pp. 3333– 48.
7. Werfel T, Allam J-P, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. [J] J Allergy Clin Immunol. 2016;138(2), pp. 336–49.
8. Atopic dermatitis - immune response and skin lesions [Internet]. QIMA Life Sciences. 2012 [cited 2022 Jul 2]. Available from: https://qima-lifesciences.com/en/atopic-dermatitis-skinlesions/
9. Atopic dermatitis [Internet]. Medlineplus.gov. [cited 2022 Jul 2]. Available from: https://medlineplus.gov/genetics/condition/atopic-dermatitis/
10. Atopic dermatitis [Internet]. Encyclopedia.pub. [cited 2022 Jul 2]. Available from: https://encyclopedia.pub/entry/5933
11. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. [J] Expert Rev Clin Immunol. 2017;13(1), pp. 15-26.
12. Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy [Internet]. 2016;8(8), pp. 853–66.
13. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy.[J] J Am Acad Dermatol. 2005;53(1 Suppl 1), pp. S17-25.
14. Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ [Internet]. 2003;327(7421), pp. 942–3.
15. Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: challenges and solutions.[J] Clin Cosmet Investig Dermatol. 2019;12, pp. 181–92.
16. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. [J] J Am Acad Dermatol. 2001;44(1 Suppl), pp. S1–12.
17. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. [J] J Am Acad Dermatol. 2001;44(1 Suppl), pp. S17-27.
18. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. [J] J Am Acad Dermatol. 2001;44(1 Suppl), pp. S17-27.
19. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. [J] Paediatr Drugs. 2013;15(4), pp. 303–10.
20. Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. [J] Front Pharmacol. 2018;9, pp.1048.
21. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? [J] J Allergy Clin Immunol. 2017;140(3), pp. 633–43.
22. Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. [J] Expert Rev Clin Immunol. 2017;13(5), pp. 415–23.
23. McDowell L, Olin B. Crisaborole: A novel nonsteroidal topical treatment for Atopic Dermatitis. [J] J Pharm Technol. 2019;35(4), pp. 172–8.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
- ISBN (Print)
- 978-1-915371-25-6
- ISBN (Online)
- 978-1-915371-26-3
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/3/20220208
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited